Literature DB >> 10491078

A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization.

O Valdenaire1, D Lepailleur-Enouf, G Egidy, A Thouard, A Barret, R Vranckx, C Tougard, J B Michel.   

Abstract

Human endothelin-converting enzyme (ECE-1) has been shown to exist as three isoforms (ECE-1a, ECE-1b and ECE-1c) diverging in their N-terminal sequence and displaying different patterns of subcellular localization. We report here the cloning of ECE-1d, a novel isoform of 767 amino acids, which is generated from the same gene via the existence of an additional promoter located upstream from the third exon of the ECE-1 gene. ECE-1d converting activity is comparable to that of the other three isoenzymes. In contrast to ECE-1b, ECE-1d is expressed at the cell surface, although less strongly than ECE-1a. We have also shown, by identifying ECE-1b and ECE-1d in rat, that the ECE-1 diversity is conserved between human and rodent, suggesting its physiological relevance. The mRNA levels of the four isoforms were assessed in the two species in various cell types, revealing some differences. In particular, the ECE-1a isoform, strongly expressed at the plasma membrane, was found to be highly expressed in primary cultures of endothelial cells but absent from primary cultures of smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491078     DOI: 10.1046/j.1432-1327.1999.00602.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  34 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Early progress in epigenetic regulation of endothelin pathway genes.

Authors:  A K Welch; M E Jacobs; C S Wingo; B D Cain
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 3.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

4.  Histochemical distribution of endothelin-converting enzyme subtypes in Podarcis sicula (Squamata, Lacertidae) tissues.

Authors:  Salvatore Valiante; Marina Prisco; Maria De Falco; Francesca Virgilio; Rosaria Sciarrillo; Piero Andreuccetti; Vincenza Laforgia; Lorenzo Varano
Journal:  J Anat       Date:  2005-10       Impact factor: 2.610

Review 5.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

6.  Association of endothelin-converting enzyme-1b C-338A polymorphism with increased risk of ischemic stroke in Chinese Han population.

Authors:  Rui Li; Min Cui; Jin Zhao; Mingming Yu; Zegang Ying; Shiming Zhou; Huadong Zhou
Journal:  J Mol Neurosci       Date:  2013-09-13       Impact factor: 3.444

7.  Regulation of vascular contractility and blood pressure by the E2F2 transcription factor.

Authors:  Junlan Zhou; Yan Zhu; Min Cheng; Deepika Dinesh; Tina Thorne; Kian Keong Poh; Dongxu Liu; Chantal Botros; Yao Liang Tang; Nichole Reisdorph; Raj Kishore; Douglas W Losordo; Gangjian Qin
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

Review 8.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 9.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Protein Kinase C Regulates the Cell Surface Activity of Endothelin-Converting Enzyme-1.

Authors:  A Ian Smith; Rebecca A Lew; Walter G Thomas; Nathalie Tochon-Danguy
Journal:  Int J Pept Res Ther       Date:  2006-05-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.